- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Emcure Pharmaceuticals Limited — Updates, 20-07-2026: Press Release
20-07-2026 | 04:20 pm
20-07-2026 | 04:20 pm
Emcure's Poviztra® (semaglutide) received CDSCO approval for MASH treatment, expanding its market into a significant unmet medical need. This makes it the first GLP-1 receptor agonist approved for this progressive liver disease in India, bolstering Emcure's metabolic portfolio.
No comments yet. Be the first to comment!